Follicular lymphoma: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CD19 27
• CD20 14
• BTK 9
• BCL-2 5
• CD22 5
• MYC 3
• EZH2 2
• PD-1 3
• PI3K 0
• PD-L1 1
• TP53 0
• CD40 0
• CD47 0
• CXCR4 0
• EGFR 0
• HDAC 0
• ABL1 0
• AKT 0
• ALK 0
• BRAF 0
• BRCA1 1
• BRCA2 1
• CCR5 0
• CD30 0
• CSF1R 1
• G6PD 0
• IL-1 0
• IL-15 0
• IL-17 0
• LAG-3 0
• MEK 0
• PPAR 0
• STAT3 0
• TFEB 0
• TIGIT 1
• TIM-3 0

24 of 39+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R43

  Preclinical development of novel dual EZH2-BRD4 inhibitor for EZH2-mutant lymphoma

  Biologica Llc· Charlotte, United States· US$385,056 awarded in fiscal year 2026· until Aug 2027

• NIH NCI · R01

  INHIBITION OF EZH2 TO ENHANCE ADOPTIVE T-CELL THERAPIES FOR CANCER

  University of Pennsylvania· Philadelphia, United States· US$704,044 awarded in fiscal year 2026· until Jul 2031

• NIH NCI · F31

  Real-Time Monitoring of Nanobubble-Labeled Chimeric Antigen Receptor T cell Trafficking via Contrast-Enhanced Ultrasound

  Case Western Reserve University· Cleveland, United States· US$50,114 awarded in fiscal year 2026· until Jun 2028

• NIH NCI · K99

  Comprehensive Profiling of Tumor and Tumor Immunity for Developing Personalized Interventions for T-cell Lymphomas

  Stanford University· Stanford, United States· US$137,266 awarded in fiscal year 2026· until Jun 2028

• NIH NCI · R01

  Translating Insights in Follicular Lymphoma for Improved Diagnosis and Classification

  New York University School of Medicine· New York, United States· US$706,137 awarded in fiscal year 2026· until Aug 2030

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Investigating the Interplay of Natural Killer Cells and Microbiome in Non-Hodgkin's Lymphoma (LINK-M)

  Luxembourg Institute of Health· Strassen, Luxembourg· EU contribution €216,240· until Aug 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  Making patient-derived tumor organoids a reliable cancer therapy testing platform (TUMORGPLAT)

  Agencia Estatal Consejo Superior de Investigaciones Cientificas· Madrid, Spain· EU contribution €245,490· until Dec 2029· 3 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  BEAT B-cell Lymphoma: Biomarkers of Effective CART19 Assessed in the Tissue Microenvironment

  Academisch Ziekenhuis Leiden· Leiden, Netherlands· EU contribution €296,296· until Apr 2027· 2 countries

8 of 33 running projects, newest first. Listed amounts together: US$20.7m + €758.0k.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma

  NCT07098364· Fred Hutchinson Cancer Center· Updated 11 Sept 2026

  “Insufficient funding”Registry text, quoted unchanged. Source

• Terminated

  A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

  NCT06256484· Atara Biotherapeutics· Updated 11 Mar 2026

  “Financial reasons”Registry text, quoted unchanged. Source

• Terminated

  A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

  NCT05336409· Century Therapeutics, Inc.· Updated 18 Dec 2025

  “Strategic decision”Registry text, quoted unchanged. Source

• Terminated

  Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

  NCT06343376· Roswell Park Cancer Institute· Updated 3 Aug 2025

  “Manufacturing issues”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

  NCT06026319· Marcela V. Maus, M.D.,Ph.D.· Source

• A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma

  NCT04594642· AstraZeneca· Source

• 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers

  NCT04464200· Memorial Sloan Kettering Cancer Center· Source

• A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies

  NCT06045910· Cancer Research UK· Source

• ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)

  NCT04049513· Malaghan Institute of Medical Research· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 4
• Mendelian Randomization Analysis 2
• CRISPR-Cas Systems 1
• Gene Expression Profiling 5
• Whole Genome Sequencing 1
• Flow Cytometry 2
• Immunohistochemistry 12
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 1
• Machine Learning 2
• Deep Learning 2
• Cohort Studies 6
• Genome-Wide Association Study 4

• Acetanilide herbicide exposure and lymphoid malignancy risk in the French AGRiculture and CANcer cohort.

  Environ Int, Dec 2025

• Diabetes, metformin use and risk of non-Hodgkin's lymphoma in postmenopausal women: A prospective cohort analysis in the Women's Health Initiative.

  Int J Cancer, Dec 2022

• Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study.

  Am J Hematol, Jun 2016

• Vitamin D status and risk of non-Hodgkin lymphoma: a meta-analysis.

  Cancer Causes Control, Aug 2014

• Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia.

  Leuk Lymphoma, Jul 2010

• Dietary vitamin D and risk of non-Hodgkin lymphoma: the multiethnic cohort.

  Br J Nutr, Sept 2009

See which targets of this disease your abstract mentions, and go to the people working on them.